Greater Than One (GTO) Group, a privately held, full-service global health and wellness marketing and communications agency network focused on providing clients with a unique framework of custom practice offerings, announced the launch of its newly designed website at https:///www.thegtogroup.com/. The new site features easy access to essential information on GTO Group’s unique offerings of GTO full-service agency, GTO Media, and GTO Enterprise.
If you are not happy with the results below please do another search
50 search results for:
Biopharma companies Gennao Bio and Juno Diagnostics raised a combined $65 million in Series A funding rounds.
New mutations, or variants, of the SARS-CoV-2 virus that causes Covid-19 are continuing to be discovered. Health officials in Florida cited a new mutation of the Brazilian strain (P.1) that they are calling P2 or P.1.1.
A new global system should be set up to respond faster to disease outbreaks, which could ensure that no future virus causes a pandemic as devastating as Covid-19, an independent World Health Organization review panel said on May 12.
Biogen Inc. exercised the company’s option to acquire TMS-007, an investigational drug for acute ischemic stroke, from TMS Co. Ltd.
Advisors to the U.S. Centers for Disease Control and Prevention (CDC) will meet on May 12 to discuss recommendations for the use of Pfizer and partner BioNTech’s Covid-19 vaccine in children aged 12 to 15.
The U.S. Food and Drug Administration authorized Pfizer and BioNTech’s Covid-19 vaccine for use in children as young as 12, widening the country’s inoculation program as vaccination rates slowed significantly. Reuters provided information that should help parents decide whether to inoculate their adolescent children.
Samsung BioLogics Co. Ltd. and Pfizer Inc. on May 12 denied a report that they were working together to produce in South Korea a Covid-19 vaccine developed by the U.S. drugmaker.
Eli Lilly will harness the power of MiNA Therapeutics’ proprietary small activating RNA (saRNA) technology platform to develop five novel drug candidates against diseases across the company’s core areas of focus.
Biogen and Capsigen forged a strategic collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to become transformative gene therapies that treat underlying genetic causes of various central nervous system and neuromuscular disorders.